Using RNAi-based screens may help better identify drug targets, especially for cancer indications, but researchers must be aware of certain pitfalls associated with the technology that could affect outcomes, according to presentations made at this year’s American Association for Cancer Research annual meeting.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.